Latest news
AstraZeneca (LSE:AZN) Signs Global Precision Oncology Diagnostics Alliance - simplywall.stsimplywall.st · Fri, 07 Aug 2026 13:51:01 GMTEvotec and Odyssey Therapeutics enter AI-enabled drug discovery collaboration in autoimmune and inflammatory diseases - The Pharma LetterThe Pharma Letter · Fri, 07 Aug 2026 10:18:54 GMTM&A Roundup: Pathos AI Enter’s Licensing Agreements with AstraZeneca & Alphamab Oncology, Curium Enters Merger Agreement with Lantheus - Pharmaceutical ExecutivePharmaceutical Executive · Tue, 04 Aug 2026 14:07:34 GMTPathos AI Secures Global Rights to Alphamab's Experimental Breast Cancer Drug in Up to $1.5 Billion Deal - Voice of HealthcareVoice of Healthcare · Tue, 04 Aug 2026 13:55:12 GMTPathos AI strikes deals with Alphamab and AstraZeneca to build AI-native oncology pipeline - Manufacturing ChemistManufacturing Chemist · Tue, 04 Aug 2026 12:09:55 GMTPathos AI Enters Collaboration and Co-Exclusive Licensing Agreement to Advance Novel ERα PROTAC for ER+ Breast Cancer into the Clinic - Business WireBusiness Wire · Tue, 04 Aug 2026 00:00:00 GMTPathos AI Enters Global Licensing Agreement with Alphamab Oncology on JSKN016, a First-in-Class TROP2/HER3 Bispecific ADC - Business WireBusiness Wire · Tue, 04 Aug 2026 00:00:00 GMTPathos AI and AstraZeneca Enter Collaboration and Co-Exclusive Licensing Agreement to Advance Novel ERa PROTAC for ER+ Breast Cancer into the Clinic - marketscreener.commarketscreener.com · Mon, 03 Aug 2026 22:00:00 GMT